These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 34537847)
1. Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study. Heo JY; Seo YB; Choi WS; Kim EJ; Jeong HW; Lee J; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Song JY J Infect Dis; 2022 Mar; 225(5):836-845. PubMed ID: 34537847 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan. Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y; Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study. Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759 [TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016. Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735 [TBL] [Abstract][Full Text] [Related]
5. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019. Liapikou A; Konstantinidis A; Kossyvaki V; Skiadas J; Menegas D; Méndez C; Beavon R; Begier E; Gessner BD; Milionis H; Tsimihodimos V; Baxevanos G; Argiriadou T; Terrovitou C; Toumbis M; Hum Vaccin Immunother; 2022 Nov; 18(5):2079923. PubMed ID: 35703733 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. McLaughlin JM; Jiang Q; Isturiz RE; Sings HL; Swerdlow DL; Gessner BD; Carrico RM; Peyrani P; Wiemken TL; Mattingly WA; Ramirez JA; Jodar L Clin Infect Dis; 2018 Oct; 67(10):1498-1506. PubMed ID: 29790925 [TBL] [Abstract][Full Text] [Related]
7. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857 [TBL] [Abstract][Full Text] [Related]
9. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience. Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277 [TBL] [Abstract][Full Text] [Related]
10. Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study. van Werkhoven CH; Bolkenbaas M; Huijts SM; Verheij TJM; Bonten MJM Clin Microbiol Infect; 2021 Jul; 27(7):995-999. PubMed ID: 32971253 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea. Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year prospective cohort. Prato R; Fortunato F; Cappelli MG; Chironna M; Martinelli D BMJ Open; 2018 Mar; 8(3):e019034. PubMed ID: 29581200 [TBL] [Abstract][Full Text] [Related]
13. Community-Acquired Pneumococcal Pneumonia in Highly Vaccinated Population: Analysis by Serotypes, Vaccination Status, and Underlying Medical Conditions. Hyun H; Jang AY; Suh JW; Bae IG; Choi WS; Seo YB; Lee J; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Kim MJ; Song JY J Korean Med Sci; 2023 Oct; 38(42):e330. PubMed ID: 37904655 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527 [TBL] [Abstract][Full Text] [Related]
15. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands. Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413 [TBL] [Abstract][Full Text] [Related]
16. Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study. Suzuki K; Kondo K; Washio M; Nakashima K; Kan S; Imai S; Yoshimura K; Ota C; Ohfuji S; Fukushima W; Hirota Y Hum Vaccin Immunother; 2019; 15(9):2171-2177. PubMed ID: 30785356 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain. Domínguez À; Soldevila N; Toledo D; Torner N; Force L; Pérez MJ; Martín V; Rodríguez-Rojas L; Astray J; Egurrola M; Sanz F; Castilla J; PLoS One; 2017; 12(2):e0171943. PubMed ID: 28187206 [TBL] [Abstract][Full Text] [Related]
19. Response to Shami et al. 'Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single dose vaccination strategy for adults in Hong Kong' (Hum Vacc Immunother 2020). Buchwald UK; Folaranmi T; Weiss T Hum Vaccin Immunother; 2021 Jan; 17(1):173-175. PubMed ID: 32614654 [TBL] [Abstract][Full Text] [Related]
20. Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine. Hsiao A; Hansen J; Timbol J; Lewis N; Isturiz R; Alexander-Parrish R; McLaughlin JM; Gessner BD; Klein NP JAMA Netw Open; 2022 Mar; 5(3):e221111. PubMed ID: 35302634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]